**Wemedoo has been featured in the German edition of MIT Technology Review (04/2026) in an interview focused on AI in medicine.

In the interview, Wemedoo co-founder Nikola Cihoric shares insights on how artificial intelligence is changing healthcare and clinical research, highlighting both its potential and its current limitations.

The interview explored how AI is transforming clinical workflows, enabling advanced data analysis, and supporting more efficient drug development, while emphasizing that it remains a tool designed to support, not replace, clinical expertise.

It also addresses key challenges facing the industry today, including the black-box nature of modern AI models, the need for globally harmonized data standards, and the regulatory complexity of continuously evolving systems.

In addition, the discussion highlights the broader shift in pharma from traditional trial-and-error approaches to data-driven design, where compounds can increasingly be evaluated digitally before entering the lab.

These perspectives closely align with Wemedoo’s ongoing work through oomnia and the COST framework, where the focus is on enabling semantic interoperability and building the data infrastructure required for scalable, AI-driven innovation in clinical research.**